Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

NCT00003532 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions

DRUG: Antineoplaston therapy (Atengenal + Astugenal)

Sponsor

Burzynski Research Institute